تقرير
أعرض في EDS

Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review.

التفاصيل البيبلوغرافية
العنوان: Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review.
المؤلفون: Asiri MS; Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.; Medicine, King Abdullah International Medical Research Center, Riyadh, SAU., Dabaliz A; Medicine, College of Medicine, Alfaisal University, Riyadh, SAU., Almutairi M; Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU., Almahbub A; Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU., Alharbi M; Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Riyadh, SAU., Almeman S; Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Riyadh, SAU., AlShieban S; Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Riyadh, SAU.; Pathology and Laboratory Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.; Pathology and Laboratory Medicine, King Abdullah International Medical Research Center, Riyadh, SAU., Alotaibi T; Medical Imaging, King Abdulaziz Medical City, Riyadh, Riyadh, SAU., Algarni M; Oncology, King Abdulaziz Medical City, Riyadh, Riyadh, SAU.; Oncology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.; Oncology, King Abdullah International Medical Research Center, Riyadh, SAU.
المصدر: Cureus [Cureus] 2023 Aug 10; Vol. 15 (8), pp. e43261. Date of Electronic Publication: 2023 Aug 10 (Print Publication: 2023).
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant disease and is considered the fourth leading cause of death among cancer patients in the United States. Mutations in the BRCA gene, which is a DNA repair gene, increase the risk of PDAC, and among all patients with PDAC, about 8%-10% have a BRCA2 mutation. The finding of gene mutations is associated with a better response to platinum-based chemotherapy. Here, we present a case of a 59-year-old male with a BRCA2 gene mutation who was diagnosed with locally advanced pancreatic cancer and had achieved a complete pathological response to the FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) regimen and Whipple procedure. We also present our literature findings on response types in BRCA2 PDAC patients, as well as consensus on the use of different therapies. The use of platinum-based chemotherapy with BRCA2 is highly recommended as the first-line treatment. Most PDAC patients remain untested for BRCA2 mutation even though their genetic status influences the selection of drug regimens. Thus, we recommend genetic testing for everyone with PDAC.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Asiri et al.)
References: Cancer. 2021 Dec 1;127(23):4393-4402. (PMID: 34351646)
Oncologist. 2011;16(10):1397-402. (PMID: 21934105)
J Clin Oncol. 2011 Aug 1;29(22):3008-15. (PMID: 21709188)
Medicina (Kaunas). 2021 Aug 30;57(9):. (PMID: 34577828)
Case Rep Oncol. 2020 Jul 29;13(2):904-910. (PMID: 32884538)
JAMA Oncol. 2017 Jun 01;3(6):774-783. (PMID: 27768182)
Front Cell Dev Biol. 2020 Sep 09;8:564601. (PMID: 33015058)
Cancer Biol Ther. 2021 Dec 2;22(10-12):532-536. (PMID: 34696697)
N Engl J Med. 2018 Dec 27;379(26):2495-2505. (PMID: 30345884)
J Clin Oncol. 2020 May 1;38(13):1378-1388. (PMID: 31976786)
Ther Adv Med Oncol. 2022 Mar 15;14:17588359221083050. (PMID: 35309086)
Br J Cancer. 2017 Apr 11;116(8):1021-1026. (PMID: 28291774)
Clin Cancer Res. 2010 Jan 1;16(1):99-108. (PMID: 20008842)
Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. (PMID: 30257212)
JCO Precis Oncol. 2019 Dec;3:1-11. (PMID: 35100679)
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074. (PMID: 29506128)
Cancer. 2020 Sep 15;126(18):4087-4088. (PMID: 32459369)
Clin Cancer Res. 2013 Oct 1;19(19):5485-93. (PMID: 23922302)
N Engl J Med. 2019 Jul 25;381(4):317-327. (PMID: 31157963)
Cancer Treat Rev. 2019 Nov;80:101895. (PMID: 31542591)
Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. (PMID: 32444418)
Br J Cancer. 2020 Feb;122(3):333-339. (PMID: 31787751)
J Clin Oncol. 2015 Oct 1;33(28):3124-9. (PMID: 25940717)
Cancer Res. 2008 Apr 15;68(8):2581-6. (PMID: 18413725)
N Engl J Med. 2017 Aug 10;377(6):523-533. (PMID: 28578601)
Br J Cancer. 2014 Sep 9;111(6):1132-8. (PMID: 25072261)
Nature. 2008 Feb 28;451(7182):1116-20. (PMID: 18264087)
فهرسة مساهمة: Keywords: brca2; folfirinox; locally advanced pancreatic adenocarcinoma; pancreatic adenocarcinoma; platinum-based therapy
تواريخ الأحداث: Date Created: 20230911 Latest Revision: 20230913
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10492221
DOI: 10.7759/cureus.43261
PMID: 37692681
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.43261